PCS499
Small molecule
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03698864 NCT03698864 · Necrobiosis Lipoidica Registry: NCT03698864 | 2 | Number of Participants With Adverse Events (12 months) 2020-02-25 | Number of Participants With Adverse Events (12 months): PCS499 900mg Twice a Day 10 Participants | not yet graded | link ↗ |
View 1 more trial
NCT04800562 NCT04800562 · Necrobiosis Lipoidica Registry: NCT04800562 | 2 | Incidence of ulcer closure as assessed by skin exam in patients treated with PCS499 as compared to placebo (~ 6 months) 2023-02-28 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.